€ million |
|
Note |
|
2025 |
|
2024 |
|---|---|---|---|---|---|---|
Profit after tax |
|
|
|
2,615 |
|
2,786 |
Items of other comprehensive income that will not be reclassified to profit or loss in subsequent periods |
|
|
|
|
|
|
Net defined benefit liability |
|
|
|
|
|
|
Changes in remeasurement |
|
|
|
486 |
|
179 |
Tax effect |
|
|
|
-57 |
|
-89 |
Changes recognized in equity |
|
|
|
429 |
|
90 |
|
|
|
|
|
|
|
Equity instruments |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
-48 |
|
37 |
Tax effect |
|
|
|
1 |
|
-6 |
Changes recognized in equity |
|
|
|
-47 |
|
30 |
|
|
|
|
381 |
|
121 |
|
|
|
|
|
|
|
Items of other comprehensive income that may be reclassified to profit or loss in subsequent periods |
|
|
|
|
|
|
Cash flow hedge reserve |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
320 |
|
92 |
Reclassification to profit or loss |
|
|
|
-243 |
|
-149 |
Reclassification to assets |
|
|
|
– |
|
– |
Tax effect |
|
|
|
-22 |
|
5 |
Changes recognized in equity |
|
|
|
55 |
|
-52 |
|
|
|
|
|
|
|
Cost of cash flow hedge reserve |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
-16 |
|
– |
Reclassification to profit or loss |
|
|
|
13 |
|
-2 |
Reclassification to assets |
|
|
|
– |
|
– |
Tax effect |
|
|
|
2 |
|
– |
Changes recognized in equity |
|
|
|
-2 |
|
-2 |
|
|
|
|
|
|
|
Currency translation difference |
|
|
|
|
|
|
Changes taken directly to equity |
|
|
|
-3,093 |
|
1,444 |
Reclassification to profit or loss |
|
|
|
-238 |
|
-15 |
Changes recognized in equity |
|
|
|
-3,331 |
|
1,429 |
|
|
|
|
-3,277 |
|
1,375 |
|
|
|
|
|
|
|
Other comprehensive income |
|
|
|
-2,896 |
|
1,496 |
Comprehensive income |
|
|
|
-281 |
|
4,282 |
thereof: attributable to shareholders of Merck KGaA, Darmstadt, Germany |
|
|
|
-283 |
|
4,272 |
thereof: attributable to non-controlling interests |
|
|
3 |
|
9 |
